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Open access under the EIn this work, a new series of arysulfonylhydrazine-1H-1,2,3-triazole derivatives were synthesized, and
their ability to inhibit the in vitro replication of HSV-1 was evaluated. Among the 1,2,
3-triazole derivatives, 1-[(500-methyl-100-(4000-ﬂuorophenylamino)-1H-1,2,3-triazol-400-yl)carbonyl]-2-(40-
meth- ylphenylsulfonyl)hydrazine and 1-[(50-methyl-10-(200,500-dichlorophenylamino)-1H-1,2,3-triazol-
40-yl)carbonyl]-2-(phenylsulfonyl)hydrazine, with IC50 values of 1.30 and 1.26 lM, respectively,
displayed potent activity against HSV-1. Because these compounds have low cytotoxicity, their selectivity
indices are high. Under the assay conditions, they have better performance than does the reference com-
pound acyclovir. The structures of all of the compounds were conﬁrmed by one- and two-dimensional
NMR techniques (1H, 13C-APT, COSY-1H  1H and HETCOR 1JCH) and by elemental analysis.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
The Herpesviridae is a large family of DNA viruses that cause
diseases in animals, including humans. There are 25 types of
viruses within this family, and they are currently divided into
three subfamilies: Alphaherpesvirinae, Betaherpesvirinae, and
Gammaherpesvirinae.1 In particular, eight or more types of her-
pes viruses of the subfamily Alphaherpesvirinae are known to
cause frequent infections in humans. Infection with the herpes
virus is categorized into one of several distinct disorders on
the basis of the site of infection.2 For instance, herpes simplex
viruses 1 and 2 (HSV-1 and HSV-2), also known as Human her-
pes viruses 1 and 2 (HHV-1 and HHV-2), commonly cause
recurrent infections affecting the skin, the mouth (gingivostoma-
titis), the lips (herpes labialis), the eyes (herpes keratitis), and
the genitals.2 Although HSV-1 is traditionally associated with
orofacial lesions, it may also cause genital infection. HSV-2 also
causes genital lesions1 that are classiﬁed as sexually transmitted
diseases (STD).3 Other syndromes related to these viruses in-
clude encephalitis, viral meningitis, neonatal herpes, and, in
immunocompromised patients, disseminated infection.4 Herpes
virus is generally transmitted by direct contact of the skin or
the mucous membranes of the mouth and genitals when the
sores are present or just before the sores appear (a process
known as viral shedding).5: +55 21 26292145.
lsevier OA license.The other viruses of the subfamily Alphaherpesvirinae3,6 include
Human herpesvirus 3 (Varicella zoster virus, VZV), Human herpes-
virus 4 (Epstein–Barr virus, EBV), Human herpesvirus 5 (Cytomeg-
alovirus, CMV), Human herpesvirus 6 (Roseolovirus), Human
herpesvirus 7 (Roseolovirus), and Human herpesvirus 8 (Kaposi’s
sarcoma-associated herpesvirus, KSHV).
Most antiherpetic drugs in clinical use, such as acyclovir (ACV,
1), penciclovir (2), and ribavirin (3), are nucleoside analogues
(Fig. 1). However, cidofovir (4) is a phosphonate molecule derived
from cytidine.5–8 Nucleoside analogues, such as 1 and 2, are pro-
drugs, because they need to be phosphorylated before they become
effective. These compounds are selectively phosphorylated only
within virus-infected cells by viral thymidine kinase (TK).9,10 Addi-
tional phosphorylation by cellular enzymes leads to the production
of acyclovir or penciclovir triphosphate, both of which compete
with the natural nucleotide, dGTP, resulting in the selective inhibi-
tion of viral DNA polymerase. Incorporation of the triphosphate
into the growing DNA chain prevents continued extension of the
chain.9,10
The emergence of virus strains that are resistant to commonly
used anti-herpesvirus drugs is a problem in clinical settings, partic-
ularly in immunocompromised individuals undergoing HSV-1
infection.11–13 Alternative approaches, such as the clinical use of
non-nucleoside drugs, have been studied.14–17 Examples of non-
nucleoside inhibitors that have been proposed as candidate drugs
for the treatment of herpes virus replication have recently been
described (Fig. 2).14–17
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Figure 2. Non nucleoside inhibitors of herpes virus replication.
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Figure 1. Antiviral drugs in clinical use against herpes virus.
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group of N-heterocyclic compounds, have been the subject of
extensive studies, because several biological properties, such as
antiplatelet,18,19 antipsychotic,20 tuberculostatic,21 antiophidic,22
and antiviral23,24 properties, have been associated with this class
of substances.
Two general synthetic methods are available for the construc-
tion of 1,2,3-triazole rings: Huisgen’s [1,3]-dipolar cycloaddition
reactions25 (in particular, copper(I)-catalyzed cycloaddition26)
and the intramolecular 1,5-electrocyclization of b-substituted
a-diazocarbonyl compounds.27,28 The latter method is more ﬂexi-
ble, because it uses readily available carbonyl compounds. With
this methodology, two pathways can be followed: (i) starting from
b-amino-a,b-unsaturated ketones or esters,29,30 followed by a diazo
transfer reaction31,32 (pathway I) and (ii) starting from a-diazo-
carbonyl compounds,18 followed by a-diazoimino formation29,33
(pathway II) (Scheme 1). The diazo donor reagents can be
3-diazo-1,3-dihydro-2H-indol-2-one28,34 and sulfonyl azides,35
such as tosyl azide, p-carboxylbenzenesulfonyl azide, and meth-
anesulfonyl azide.
Recently, we have published the design and synthesis of
N-amino-1,2,3-triazole derivatives and an evaluation of their
antiviral activity against Cantagalo virus (CTGV) replication in cell
culture. In this study, it was found that the compound 1-(4-ﬂuoro-
phenylamino)-5-methyl-1H-[1,2,3]-triazole-4-carbohydrazide,24
exhibited a signiﬁcant effect against CTGV. CTGV was the ﬁrst
sample isolated during a poxvirus outbreak in 1999 in Rio de Ja-
neiro state, and it was characterized as a vaccinia virus (VACV)
strain.
As part of an ongoing research program on the synthesis of
new bioactive N-heterocycles by using diazocarbonyl com-
pounds,18–20,22,24 we herein report the synthesis and anti-HSV-1
evaluation of a family of 1,2,3-triazole derivatives 9a–i bearing
an arylsulfonylhydrazide function at position C-4 of the azolic ring.In addition, we investigated the effect of different substituents at-
tached to N-phenyl ring on biological activity (Scheme 2).
2. Results and discussion
2.1. Chemistry
The synthesis of new arylsulfonylhydrazide-1,2,3-triazole
derivatives 9a–i is shown in Scheme 1. The ethyl N-substituted-
phenylamino-4-carbethoxy-1H-1,2,3-triazoles 10a–e were pre-
pared in moderate yields by the condensation of ethyl 2-diazoace-
toacetate with substituted phenylhydrazine hydrochlorides
according to the method outlined in our previous report.23 These
compounds were converted into corresponding carbohydrazides
11a–e on treatment with hydrazine hydrate in reﬂuxing ethanol.24
The new class of triazoles 9a–i was prepared by the condensa-
tion of compounds 11a–e with suitable arylsulfonyl chlorides
12a–c in pyridine. The yields of these reactions (9a–i) are listed
in Table 1.
2.2. Materials and methods
2.2.1. Cells and virus
African green monkey kidney cells (Vero) were cultured in
Dulbecco’s Modiﬁed Eagles Medium (DMEM) with 5% fetal bovine
serum (FBS), 100 U/mL penicillin and 100 lg/mL streptomycin and
then incubated at 37 C in 5% CO2. Vero cells were infected with
HSV-1 to obtain virus stock at a multiplicity of infection36 (MOI)
of 0.1 at 37 C for 1 h. At 48 h post-infection (p.i.), cell supernatants
were centrifuged and stored at 70 C.
2.2.2. Cytotoxicity assay
Monolayers of Vero cells in 96-multiwell plates (104 cells/well)
were treated with different concentrations of the test compounds
R1
N O
RH
Me
NaH MsNH2
N
N
N
O
R1
Me
R
N
N
N
R
H3C
R1OC
N
N
N
R3
H
R2
O
R2 H
OO
N2
R3NH2 N
N
N
R3
O
R2
+
R = Bn and R1 = OEt
R = Bn and R1 = Me
R = n-Bu and R1 = OEt
R2 = H and R3 = 4-FC6H5
R2 = Thiophene-2-yl and R3 = BrCH2CH2
R2 = 2,5-Me2-furan -3-yl and R3 = C6H5
Pathway
I
Pathway
II
Ms N3
Equation 1
Equation 2
Scheme 1. Methods for preparing triazoles from a-diazoimines.
N
N N Me
O
O
N H
10a, R1= R2 = R3= H
10b, R1=R3= H and R2= F
10c, R1=R3= H and R2= Cl
10d, R1=R3= H and R2= Br
10e, R1=R3= Cl and R2= H
NH2NH2.H2O (80%)
EtOH, 2h, Δ
12a, R4 =H
12b, R4 = Me
12c, R4 = OMe
pyridine
N S
H
O
O
R4
4-5h, 25ºC
SO2Cl
R3
N
N N Me
NHNH2
O
N H
N
N N Me
N
O
N H
H
R1
R2
R3
R1
R2
R3
R1
R2
R311a, R1= R2 = R3= H
11b, R1=R3= H and R2= F
11c, R1=R3= H and R2= Cl
11d, R1=R3= H and R2= Br
11e, R1=R3= Cl and R2= H
9a, R1= R2 = R3= R4 = H
9b, R1= R2 = R3= H and R4 = Me
9c, R1=R2= R3= H and R4 = OMe
9d, R1= R3= H, R2 = F and R4 = Me
9e, R1=R3= R4 = H and R2= Cl
9f , R1=R3= R4 = H and R2= Br
9g, R1=R3= H, R2= Br and R4 = Me
9h, R1=R3= H, R2= Br and R4 = OMe
9i, R1=R3= Cl and R2= R4 = H
Scheme 2. Synthetic pathways used for the preparation of 9a–i.
1862 A. K. Jordão et al. / Bioorg. Med. Chem. 19 (2011) 1860–1865for 72 h. Then, XTT (2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide) was added to each well at a ﬁnal con-
centration of 2.5 mg/mL in the presence of phenazine methosulfate
(PMS) at 32 lg/mL. After a 4 h incubation period, the optical den-
sity was measured using a spectrophotometer with 492-nm test
and 620-nm reference wavelengths. For comparison, acyclovir
was used as a positive control. The 50% cytotoxic concentration
(CC50) was calculated by linear regression analysis of the dose-
response curves obtained from the data.
2.2.3. Anti-HSV-1 assays
Vero cells (104 cells/well) in 96-well plates were infected with
HSV-1 at 100 CCID50/well for 1 h. After that, virus inoculumwas re-
moved, cells were washed and a medium containing 50 lM of the
test compounds was added. After incubation for 72 h, XTT/PMS
solution was added to each well to measure the ability of the com-
pounds to inhibit the HSV-1-induced cytopathic effect, as de-
scribed above.37
To determine the IC50 values of the test compounds, Vero cells
in a 6-well plates were infected with HSV-1 at an MOI of 5 for
1 h at 37 C. After this period of time, cells were washed and
treated with different concentrations of the most effect testcompounds. After a 24 h incubation period, HSV-1-infected cells
were lysed, the supernatant of these cells was harvested and tit-
tered as described in the previous paragraph.37 Acyclovir was used
as a positive control. The 50% inhibitory concentration (CC50) was
calculated by linear regression analysis of the dose-response
curves obtained from the data.
2.3. Anti-HSV-1 activity
The 1,2,3-triazole derivatives 9a–i were evaluated for their
inhibitory effect on HSV-1 (Table 2). Of the nine tested compounds,
ﬁve inhibited virus replication by more than 70% at 50 lM after
72 h post-infection. The bioactive compounds 9a (R1 = R2 = R3 =
R4 = H), 9d (R1 = H, R2 = F, R3 = H and R4 = Me), 9g (R1 = H, R2 = Br,
R3 = H and R4 = Me), 9h (R1 = H, R2 = Br, R3 = H and R4 = OMe), and
9i (R1 = Cl, R2 = H, R3 = Cl and R4 = H) inhibited HSV-1 replication
by 79%, 88%, 69%, 77%, and 71%, respectively. The positive control
acyclovir (ACV) inhibited 95% of HSV-1 replication under these
experimental conditions.
The cytotoxicity and antiviral potency of the most-active tria-
zoles 9a, 9b, 9d, 9h, and 9i were evaluated (Table 3). These azo-
compounds were less cytotoxic (CC50 = 1512, 863, 1266, 971, and
Table 2
Antiviral activity for 1,2,3-triazole derivatives 9a–i
N S
H
O
O
R4
N
N N Me
N
O
N H
H
R1
R2
R3
9a-i
Compounds R1 R2 R3 R4 % of inhibition of virus
yielda (HSV-1)
9a H H H H 79 ± 2.3
9b H H H Me 37 ± 1.2
9c H H H OMe 54 ± 3.2
9d H F H Me 88 ± 2.0
9e H Cl H H 57 ± 4.3
9f H Br H H 31 ± 1.5
9g H Br H Me 69 ± 2.2
9h H Br H OMe 77 ± 4.5
9i Cl H Cl H 71 ± 3.9
ACV — — — — 95 ± 1.2
a The experimental concentrations of triazole derivatives 9a–i were 50 lM and
ACV concentration was 50 lM. Results are presented as means of triplicate
experiments. ACV-acyclovir has been included for comparison purposes.
Table 1
Yields and mp for arylsulfonylhydrazide-1,2,3-triazoles 9a–i
N S
H
O
O
R4
N
N N Me
N
O
N H
H
R1
R2
R3
9a-i
Compounds R1 R2 R3 R4 Mp (C) Yield (%)
9a H H H H 180–182 87
9b H H H Me 207–215 73
9c H H H OMe 187–190 67
9d H F H Me 208–210 60
9e H Cl H H 188–191 47
9f H Br H H 185–193 69
9g H Br H Me 207–208 78
9h H Br H OMe 167–169 93
9i Cl H Cl H 235–238 83
Table 3
Cytotoxicity, anti-HSV-1 activity, and selectivity index in Vero cells for triazole
derivatives 9a, 9d, 9h, and 9i
Compounds R1 R2 R3 R4 CC50a (lM) IC50b (lM) SIc
9a H H H H 1512 ± 34 19 ± 0.02 80
9d H F H Me 1266 ± 62 1.3 ± 0.04 974
9h H Br H OMe 971 ± 23 37 ± 3.0 26
9i Cl H Cl H 1174 ± 52 1.26 ± 0.03 932
ACV — — — — 860 ± 25 0.99 ± 0.02 869
Acyclovir was used as a positive control. The mean values ± standard deviations are
representative of three independent experiments.
a CC50: cytotoxic concentration (lM) or concentration required to reduce the
viability of host cells by 50%. The cytotoxicity was determined by XTT assay and the
anti-HSV-1 activity by viral plaque number reduction assay.
b IC50: 50% inhibitory concentration, deﬁned as the concentration (lM) that
inhibited 50% of viral plaque formation when compared to untreated controls.
c SI: selectivity index is the ratio between CC50 and IC50 values.
A. K. Jordão et al. / Bioorg. Med. Chem. 19 (2011) 1860–1865 18631174 lM) than was acyclovir, which presented a CC50 of
860 ± 54 lM, under our assay conditions.38 Only two of these com-
pounds, 9d and 9i, with IC50 values of 1.30 and 1.26 lM, respec-
tively, displayed potent activity against HSV-1. Selective index
(SI) values, which represent the in vitro antiviral potency and
safety of a candidate antiviral drug, of 9d and 9i are comparable
to the ACV SI (Table 3). The antiviral activity of these compounds
is comparable to that of other molecules studied by our group36
and described elsewhere.37
These results strongly suggest that compounds 9d and 9i could
be considered as promising candidates for the development of new
derivatives with anti-HSV-1 activity and for additional studies con-
cerning the antiviral activity of this group of compounds.
3. Conclusion
In summary, a new series of arysulfonylhydrazide-1,2,3-tria-
zoles, 9a–i, have been synthesized and evaluated for their antiviralactivities against HSV-1 replication in cell culture. Among these
N-heterocyclic derivatives, compounds 9d and 9i were the most
promising molecules with potent anti-HSV-1 activity. These com-
pounds exhibited lower cytotoxicity and higher selectivity indices
than did the reference compound acyclovir.
These 1,2,3-triazole analogues, 9d and 9i, represent promising
structures for the development of new compound analogues with
anti-HSV-1 activity and for future in vivo analysis.
4. Experimental section
Melting points were determined with a Fisher-Johns instrument
and are uncorrected. Infrared (IR) spectra were recorded on an ABB
FTLA2000-100 spectrophotometer in KBr pellets. NMR spectra, un-
less otherwise stated, were obtained in Me2SO-d6 or CDCl3 by using
a Varian Unity Plus 300 MHz spectrometer. Chemical shifts (d) are
expressed in ppm and the coupling constants (J) in Hertz. Column
chromatography puriﬁcation was performed on silica gel ﬂash
from Across. Reactions were routinely monitored by thin-layer
chromatography (TLC) on Silica Gel pre-coated F254 by using Merck
plates. Microanalyses were performed on a Perkin–Elmer Model
2400 instrument, and all values were within ±0.4% of the calcu-
lated compositions.
4.1. Chemistry
4.1.1. General procedure for the preparation of the 1,2,3-triazole
derivatives 9a–i
To a stirred solution of 4-carbohydrazide-1,2,3-triazole deriva-
tives 10a–e (1 mmol) in pyridine (10 mL), the desired aryl sulfonyl-
chlorides (1.2 mmol) were added at 0 C. The resulting mixture
was stirred at room temperature for 4–5 h. After this period, the
reaction mixture was diluted with 1 M HCl and extracted with
ethyl acetate (4  25 mL). The combined layers were washed with
sodium bicarbonate solution, ﬁltered, and dried over anhydrous
Na2SO4. Evaporation of the solvent under vacuum produced the
crude products that were puriﬁed by column chromatography
employing EtOAc/hexane mixture as eluent giving:
4.1.1.1. 1-[(50-Methyl-10-(phenylamino)-1H-1,2,3-triazol-40-yl)-
carbonyl]-2-(phenylsulfonyl)hydrazine 9a. As a white solid by
condensation of 11a with benzenesulfonyl chloride. IR (KBr) mmax
(cm1) 3248 (N–H), 1685 (C@O); 1H NMR (300.00 MHz, DMSO-
d6) d 2.38 (s, 3H, CH3), 6.42–6.45 (m, 2H), 6.89–6.94 (m, 1H),
7.21–7.27 (m, 2H), 7.54–7.59 (m, 2H), 7.65–7.68 (m, 1H), 7.84–
7.87 (m, 2H), 10.12 (br s, 1H, N–H) ppm. 13C NMR (75 MHz,
DMSO-d6) d 8.0 (CH3), 112.9 (C-20 and C-60), 121.2 (C-40), 127.6
(C-30 and C-50), 128.9 (C-200 and C-600), 129.5 (C-300 and C-500),
1864 A. K. Jordão et al. / Bioorg. Med. Chem. 19 (2011) 1860–1865133.0 (C-400), 135.6 (C-4 or C-5), 138.1 (C-4 or C-5), 146.1 (C-10),
159.9 (C@O) ppm. Anal. Calcd for C16H16N6O2S: C, 51.60; H, 4.33;
N, 22.57. Found: C, 51.57; H, 4.67; N, 21.48.
4.1.1.2. 1-[(500-Methyl-100-(phenylamino)-1H-1,2,3-triazol-400-yl)-
carbonyl]-2-(40methylphenylsulfonyl)hydrazine 9b. As a white
solid by condensation of 11awith p-tolylsulfonyl chloride chloride.
IR (KBr) mmax (cm1) 3306 (N–H); 1685 (C@O); 1H NMR
(300.00 MHz, DMSO-d6) d 2.28 (s, 3H, CH3), 2.38 (s, 3H, CH3),
6.43–6.46 (m, 2H), 6.90–6.95 (m, 1H), 7.22–7.27 (m, 2H), 7.36 (d,
2H, J = 8.2), 7.74 (d, 2H, J = 8.5), 10.12 (br s, 1H, N–H) ppm. 13C
NMR (75 MHz, DMSO-d6) d 7.9 (CH3), 20.9 (CH3), 112.8 (C-20 and
C-60), 121.4 (C-40), 127.6 (C-2’’ and C-6’’), 129.2 (C-30 and C-50),
129.4 (C-300 and C-500), 135.5 (C-100), 136.4 (C-4 or C-5), 137.8 (C-4
or C-5), 143.2 (C-400), 145.9 (C-10), 146.1 (C-3’’ and C-5’’), 159.8
(C@O) ppm. Anal. Calcd for C17H18N6O3S: C, 52.84; H, 4.70; N,
21.75. Found: C, 53.55; H, 5.09; N, 20.98.
4.1.1.3. 1-[(500-Methyl-100-(phenylamino)-1H-1,2,3-triazol-400-yl)-
carbonyl]-2-(40methoxylphenylsulfonyl)hydrazine 9c. As a
white solid by condensation of 11a with p-methoxybenzenesulfo-
nyl chloride. IR (KBr) mmax (cm1) 3236 (N–H); 1675 (C@O); 1H
NMR (300.00 MHz, DMSO-d6) d 2.28 (s, 3H, CH3), 3.81 (s, 3H,
OCH3), 6.42–6.45 (m, 2H), 6.89–6.94 (m, 1H), 7.08 (d, 2H, J = 8.9),
7.21–7.27 (m, 2H), 7.78 (d, 2H, J = 8.9), 9.81 (br s, 1H, N–H),
10.12 (br s, 1H, N–H), 10.56 (br s, 1H, NH–C) ppm. 13C NMR
(75 MHz, DMSO-d6) d 8.0 (CH3), 55.6 (OCH3), 112.6 (C-200 and C-
600), 114.0 (C-300 and C-500), 121.5 (C-40), 129.4 (C-20 and C-60),
129.9 (C-30 and C-50), 130.7 (C-100), 135.6 (C-4 or C-5), 137.9 (C-4
or C-5), 146.1 (C-10), 159.8 (C-400), 162.6 (C@O) ppm. Anal. Calcd
for C17H18N6O4S: C, 50.74; H, 4.51; N, 20.88. Found: C, 50.15; H,
4.80; N, 19.92.
4.1.1.4. 1-[(500-Methyl-100-(4000-ﬂuorophenylamino)-1H-1,2,3-tria-
zol-400-yl)carbonyl]-2-(40methylphenylsulfonyl)hydrazine 9d. As
a white solid by condensation of 11b with p-tolylsulfonyl chloride.
IR (KBr) mmax (cm1) 3218 (N–H); 1679 (C@O); 1H NMR
(300.00 MHz, DMSO-d6) d 2.30 (s, 3H, CH3), 2.38 (s, 3H, CH3),
6.49 (dd, 2H, J = 9.0; 4.6), 7.08 (dd, 2H, J = 8.9; 8.8), 7.36 (d, 2H,
J = 8.1), 7.74 (d, 2H, J = 8.3), 10.10 (br s, 1H, N–H) ppm. 13C NMR
(75 MHz, DMSO-d6) d 7.8 (CH3), 20.9 (CH3), 114.6 (J = 8.3; C-20
and C-60), 115.9 (J = 8.3; C-30 and C-50), 127.5 (C-200 and C-600),
129.2 (C-300 and C-500), 135.6 (C-100), 136.4 (C-4 or C-5), 137.7 (C-4
or C-5), 142.4 (J = 2.3; C-10), 157.2 (J = 237.4; C-40), 159.7 (C@O)
ppm. Anal. Calcd for C17H17FN6O3S: C, 50.49; H, 4.24; N, 20.78.
Found: C, 50.26; H, 4.54; N, 20.15.
4.1.1.5. 1-[(50-Methyl-10-(400-chlorophenylamino)-1H-1,2,3-tria-
zol-40-yl)carbonyl]-2-(phenylsulfonyl)hydrazine 9e. As a white
solid by condensation of 11c with benzenesulfonyl chloride. IR
(KBr) mmax (cm1) 3310 (N–H); 1677 (C@O); 1H NMR
(300.00 MHz, DMSO-d6) d 2.28 (s, 3H, CH3), 6.47 (d, 2H, J = 8.9),
7.28 (d, 2H, J = 8.9), 7.54–7.59 (m, 2H), 7.62–7.69 (m, 1H),
7.84–7.87 (m, 2H), 9.97 (br s, 1H, N–H), 10.12 (br s, 1H, N–H),
10.61 (br s, 1H, N–H) ppm. 13C NMR (75 MHz, DMSO-d6) d 7.8
(CH3), 114.5 (C-20 and C-60), 125.1 (C-40), 127.5 (C-30 and C-50),
128.8 (C-200 and C-600), 129.2 (C-300 and C-500), 132.8 (C-400), 135.6
(C-4 or C-5), 137.8 (C-4 or C-5), 139.4 (C-100), 144.9 (C-10), 159.7
(C@O) ppm.
4.1.1.6. 1-[(50-Methyl-10-(400-bromophenylamino)-1H-1,2,3-triazol-
40-yl)carbonyl]-2-(phenylsulfonyl)hydrazine 9f. As a white
solid by condensation of 11d with benzenesulfonyl chloride. IR
(KBr) mmax (cm1) 3311 (N–H); 1677 (C@O); 1H NMR
(300,00 MHz, DMSO-d6) d 2.27 (s, 3H, CH3), 6.42 (d, 2H, J = 9.0),
7.41 (d, 2H, J = 9.0), 7.56–7.59 (m, 2H), 7.62–7.67 (m, 1H),7.84–7.87 (m, 2H), 10.30 (br s, 1H, N–H) ppm. 13C NMR (75 MHz,
DMSO-d6) d 7.8 (CH3), 112.7 (C-40), 115.0 (C-20 and C-60), 127.5
(C-30 and C-50), 128.8 (C-200 and C-600), 132.1 (C-300 and C-500),
135.6 (C-400), 137.9 (C-4 or C-5), 139.3 (C-4 or C-5), 139.3 (C-100),
145.3 (C-10), 159.7 (C@O) ppm.
4.1.1.7. 1-[(500-Methyl-100-(4000-bromophenylamino)-1H-1,2,3-
triazol-400-yl)carbonyl]-2-(40-methylphenylsulfonyl)hydrazine
9g. As a white solid by condensation of 11d with p-tolylsulfo-
nyl chloride. IR (KBr) mmax (cm1) 3301 (N–H); 1678 (C@O); 1H
NMR (300.00 MHz, DMSO-d6) d 2.28 (s, 3H, CH3), 2.38 (s, 3H,
CH3), 6.42 (d, 2H, J = 8.9), 7.36 (d, 2H, J = 8.2), 7.41 (d, 2H, J = 8.9),
7.74 (d, 2H, J = 8.2), 10.28 (br s, 1H, N–H) ppm. 13C NMR
(75 MHz, DMSO-d6) d 7.8 (CH3), 20.9 (CH3), 112.7 (C-40), 114.9
(C-20 and C-60), 127.5 (C-200 and C-600), 129.2 (C-300 and C-500),
132.1 (C-30 and C-50), 135.6 (C-100), 136.4 (C-4 or C-5), 137.8 (C-4
or C-5), 143.1 (C-400), 145.3 (C-10), 159.7 (C@O) ppm. Anal. Calcd
for C17H17BrN6O3S: C, 43.88; H, 3.68; N, 18.06. Found: C, 44.07;
H, 4.01; N, 17.40.
4.1.1.8. 1-[(500-Methyl-100-(4000-bromophenylamino)-1H-1,2,
3-triazol-400-yl)carbonyl]-2-(40-methoxylphenylsulfonyl)hydra-
zine 9h. As a white solid by condensation of 11d with
p-methoxybenzenesulfonyl chloride. IR (KBr) mmax (cm1) 3231
(N–H); 1684 (C@O); 1H NMR (300.00 MHz, DMSO-d6) d 2.28 (s,
3H, CH3), 2.38 (s, 3H, CH3), 6.42 (d, 2H, J = 8.8), 7.08 (d, 2H,
J = 9.0), 7.41 (d, 2H, J = 8.8), 7.78 (d, 2H, J = 9.0), 9.81 (br s, 1H,
N–H), 10.31 (br s, 1H, N–H), 10.57 (br s, 1H, N–HC) ppm. 13C
NMR (75 MHz, DMSO-d6) d 7.9 (CH3), 55.6 (CH3), 112.8 (C-40),
114.0 (C-20 and C-60), 115.0 (C-300 and C-500), 129.9 (C-200 and
C-600), 130.7 (C-100), 132.1 (C-30 and C-50), 135.7 (C-4 or C-5),
137.8 (C-4 or C-5), 145.3 (C-10), 159.7 (C-400), 162.6 (C@O) ppm.
Anal. Calcd for C17H17BrN6O4S: C, 42.42; H, 3.56; N, 17.46. Found:
C, 42.97; H, 3.84; N, 17.70.
4.1.1.9. 1-[(50-Methyl-10-(200,500-dichlorophenylamino)-1H-1,2,3-
triazol-40-yl)carbonyl]-2-(phenylsulfonyl)hydrazine 9i. As
a white solid by condensation of 11e with benzenesulfonyl chlo-
ride. IR (KBr) mmax (cm1) 3248 (N–H); 1685 (C@O); 1H NMR
(300.00 MHz, DMSO-d6) d 2.28 (s, 3H, CH3), 6.02 (d, 1H, J = 2.5),
7.03 (dd, 1H, J = 2.5, 8.3), 7.49–7.58 (m, 3H), 7.63–7.68 (m, 1H),
7.86 (dd, 2H, J = 1.5, 7.3), 10.01 (br s, 1H, N–H), 10.24 (br s, 1H,
N–H), 10.68 (br s, 1H, NH–C) ppm. 13C NMR (75 MHz, DMSO-d6)
d 7.9 (CH3), 113.1 (C-60), 116.7 (C-50), 122.1 (C-40), 127.5 (C-200
and C-600), 128.5 (C-300 and C-500), 131.4 (C-30), 132.7 (C-20), 132.8
(C-400), 135.7 (C-4 or C-5), 138.2 (C-4 or C-5), 139.2 (C-10), 142.8
(C-100), 159.7 (C@O) ppm. Anal. Calcd for C16H14Cl2N6O3S: C,
43.55; H, 3.20; N, 19.04. Found: C, 43.37; H, 3.50; N, 19.36.Acknowledgments
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